Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-09
2011-08-09
Bunner, Bridget E (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S327000, C530S328000, C530S329000, C530S350000, C530S387300, C530S388220, C530S391300
Reexamination Certificate
active
07994285
ABSTRACT:
The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.
REFERENCES:
patent: 5648464 (1997-07-01), Artavanis-Tsakonas et al.
patent: 5780300 (1998-07-01), Artavanis-Tsakonas et al.
patent: 5786158 (1998-07-01), Artavanis-Tsakonas et al.
patent: 5789195 (1998-08-01), Artavanis-Tsakonas et al.
patent: 6083904 (2000-07-01), Artavanis-Tsakonas et al.
patent: 6090922 (2000-07-01), Artavanis-Tsakonas et al.
patent: 6149902 (2000-11-01), Artavanis-Tsakonas et al.
patent: 6436650 (2002-08-01), Artavanis-Tsakonas et al.
patent: 6692919 (2004-02-01), Artavanis-Tsakonas et al.
patent: 2002/0151487 (2002-10-01), Nickoloff et al.
patent: 2003/0186290 (2003-10-01), Tournier-Lasserve et al.
patent: 2004/0058443 (2004-03-01), Artavanis-Tsakonas et al.
patent: 2004/0242482 (2004-12-01), Gehring et al.
patent: 2005/0112121 (2005-05-01), Artavanis-Tsakonas et al.
patent: 2005/0158859 (2005-07-01), Artavanis-Tsakonas et al.
patent: 2005/0208027 (2005-09-01), Conboy et al.
patent: 2006/0002924 (2006-01-01), Bodmer et al.
patent: 2007/0003983 (2007-01-01), Artavanis-Tsakonas et al.
patent: 2008/0107648 (2008-05-01), Noguera et al.
patent: 2008/0118520 (2008-05-01), Li et al.
patent: 2008/0226621 (2008-09-01), Fung et al.
patent: 2 777 285 (1999-10-01), None
patent: 95/15982 (1995-06-01), None
patent: 00/20576 (2000-04-01), None
patent: 02/24221 (2002-03-01), None
patent: 2006/015375 (2006-02-01), None
patent: 2006/017173 (2006-02-01), None
patent: 2006/053063 (2006-05-01), None
patent: 2006/068822 (2006-06-01), None
patent: 2008/057144 (2008-05-01), None
patent: 2008/150525 (2008-11-01), None
Li et al. beta-Endorphin omission analogs: dissociation of immunoreactivity from other biological activities.Proc Natl Acad Sci U S A. 77(6):3211-3214, 1980.
Lederman et al. A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4. Mol Immunol. 28(11):1171-1181, 1991.
Daniel et al. Virology 202: 540-549, 1994.
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotech 18(1): 34-39, 2000.
Bork, A. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome Res 10: 398-400, 2000.
Doerks et al. Protein annotation: detective work for function prediction. Trends in Genetics 14(6): 248-250, 1998.
Smith et al. The challenges of genome sequence annotation or “The devil is in the details”. Nature Biotech 15: 1222-1223, 1997.
Brenner, S.E. Errors in genome function. Trends in Genetics 15(4): 132-133, 1999.
Bork et al. Go hunting in sequence databases but watch out for the traps. Trends in Genetics. 12(10): 425-427, 1996.
Ngo et al. Computational complexity, protein structure prediction, and the Levinthal paradox. The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.
Wells. J.A. Additivity of mutational effects in proteins. Biochemistry 29 (37): 8509-8517, 1990.
Davies et al., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding”Immunotechnology2:169-179 (1996).
Holt et al., “Domain antibodies: proteins for therapy”Trends Biotechnol. 21(11):484-490 (Nov. 2003).
Joutel et al., “Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis”Lancet358:2049-2051 (2001).
Jurynczyk et al., “Notch3 Inhibition in Myelin-Reactive T Cells Down-Regulates Protein Kinase Cθ and Attenuates Experimental Autoimmune Encephalomyelitis”Journal of Immunology180(4):2634-2640 (2008).
Li et al., “Modulation of Notch Signaling by Antibodies Specific for the Extracellular Negative Regulatory Region of NOTCH3”Journal of Biological Chemistry283(12):8046-8054 (Mar. 21, 2008).
PCT International Search Report mailed Dec. 23, 2008, in counterpart PCT Application No. PCT/US2007/081799, filed Oct. 18, 2007.
Allenspach et al., “Notch signaling in cancer”Cancer Biol Ther. 1(5):466-76 (2002).
Anastasi et al., “Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes”J Immunol. 171(9):4504-11 (Nov. 2003).
Androutsellis-Theotokis et al., “Notch signalling regulates stem cell numbers in vitro and in vivo”Nature442:823-6 (Aug. 2006).
Artavanis-Tsakonas et al., “Notch Signaling”Science268:225-232 (Apr. 14, 1995).
Artavanis-Tsakonas et al., “Notch Signaling: Cell Fate Control and Signal Integration in Development”Science284:770-776 (1999).
Aster et al., “The folding and structural integrity of the first LIN-12 module of human Notch1 are calcium-dependent”Biochemistry38(15):4736-42 (Apr. 1999).
Bellavia et al., “Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis”Proc Natl Acad Sci U S A. 99(5):3788-93 (Mar. 2002).
Bocchetta et al., “Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells”Oncogene22(1):81-9 (Jan. 2003).
Bolos et al., “Notch signaling in development and cancer”Endocr Rev. 28(3):339-63 (May 2007).
Bray, “Notch signalling: a simple pathway becomes complex”Nat Rev Mol Cell Biol. 7(9):678-89 (Sep. 2006).
Buchler et al., “The Notch signaling pathway is related to neurovascular progression of pancreatic cancer”Ann Surg. 242(6):791-800 (Dec. 2005).
Chiba, “Notch signaling in stem cell systems”Stem Cells24(11):2437-47 (Nov. 2006).
Coffman et al., “Expression of an extracellular deletion of Xotch diverts cell fate inXenopusembryos”Cell73(4):659-71 (May 1993).
Domenga et al., “Notch3 is required for arterial identity and maturation of vascular smooth muscle cells”Genes Dev. 18(22):2730-5 (Nov. 2004).
Ellisen et al., “TAN-1, the human homolog of theDrosophilanotch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms”Cell66(4):649-61 (Aug. 1991).
Fan et al., “Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors”Cancer Research66(15):7445-52 (Aug. 2006).
Flynn et al., “The role of Notch receptor expression in bile duct development and disease”J Pathol. 204(1):55-64 (Sep. 2004).
Fre et al., “Notch signals control the fate of immature progenitor cells in the intestine”Nature435:964-8 (Jun. 2005).
Gordon et al., “Structural basis for autoinhibition of Notch”Nat Struct Mol Biol. 14(4):295-300 (Apr. 2007).
Haruki et al., “Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers”Cancer Research65(9):3555-61 (May 2005).
Hedvat et al., “Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma”Br J Haematol. 122(5):728-44 (Sep. 2003).
Heller et al., “Amino Acids at the Site of V.-J. Recombination Not Encoded by Germline Sequences”Journal of Experimental Medicine166:637-646 (1987).
Houde et al., “Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines”Blood104(12):3697-704 (Dec. 2004).
Hu et al., “Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors”Am J Pathol. 168(3):973-90 (Mar. 2006).
Jang et al., “Notch signaling as a target in multimodality cancer therapy”Curr Opin Mol Ther. 2(1):55-65 (Feb. 2000)
Fung Sek Chung
Li Kang
Yao Zhengbin
Bunner Bridget E
Genentech Inc.
Pasqualone Danielle M.
LandOfFree
Anti-Notch3 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-Notch3 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-Notch3 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2704234